Sign in

Mary Kate

Research Analyst at Citigroup Inc.

Mary Kate O'Hare is Head of Art Advisory at Citi, specializing in providing strategic art market guidance for private and institutional clients. While not a financial analyst, she oversees the art advisory and valuation strategy at Citigroup’s wealth division, linking art investment trends to wealth management services. O'Hare joined Citi after a career spanning roles at Christie’s and Rutgers University, leveraging deep expertise in art markets and advisory. She holds advanced academic credentials in art history and serves as a leader in global art advisory circles.

Mary Kate's questions to Kiniksa Pharmaceuticals International (KNSA) leadership

Question · Q3 2025

Mary Kate asked about the patient and physician feedback regarding the increasing duration of ARCALYST therapy, specifically from longer-term users.

Answer

John Paolini (CMO, Kiniksa Pharmaceuticals) discussed the academic literature's appreciation for disease duration and the necessity of long-term treatment, citing a 99.5% reduction in event rates with continuous therapy. Ross Moat (Chief Corporate and Commercial Officer, Kiniksa Pharmaceuticals) added that healthcare professionals appreciate the high access rates and quick patient onboarding, while patients report high satisfaction due to ARCALYST's efficacy and tolerability as a long-term treatment for a chronic disease.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts